Ptc Therapeutics (PTCT) Free Cash Flow (2012 - 2026)

Ptc Therapeutics' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$60.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 106.94% year-over-year to -$60.2 million in Q1 2026; TTM through Mar 2026 was -$217.5 million, a 131.1% decrease from a year earlier, with the FY2025 full-year figure at $711.1 million, up 759.88% from the prior year.
• Free Cash Flow eased to -$60.2 million in Q1 2026 per PTCT's latest filing, from -$27.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $868.4 million in Q1 2025 and bottomed at -$142.9 million in Q4 2022.
• The 5-year median for Free Cash Flow is -$59.6 million (2025), against an average of -$43823.5.
• Across the five-year window, Free Cash Flow sank 271.31% in 2024 and jumped 1319.55% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$142.9 million in 2022, then climbed by 25.91% to -$105.9 million in 2023, then soared by 74.17% to -$27.3 million in 2024, then dropped by 2.1% to -$27.9 million in 2025, then sank by 115.81% to -$60.2 million in 2026.
• Per Business Quant, the three latest PTCT Free Cash Flow figures stand at -$60.2 million (Q1 2026), -$27.9 million (Q4 2025), and -$69.7 million (Q3 2025).